RE:RE:They act like big pharma. That's a problemAs they have stated in the new Presentation, there is both a financial plan and a plan around answering whatever questions they can from the trial data. The financial plan will have to be elaborated on in the next quarterly call in Feb and given how analysts have always focused on those numbers to begin with, for once all their questions will actually be some of the most important. So we will find out the expense cuts and revenue forecast to get to EBITDA breakeven as they are budgeting for. I'm sure they'll be some wiggle room plus/minus based on the overall economy, but the outline of how to achieve it needs to be discussed.
As for RD, trials, what they're thinking, given they state they hope to re-enroll in the 1H and everything around TH1902 is based on hard decision-trees, they may not have concluded enough to dig in to it by February. I would think they'd talk with some generalities, but I hope analysts will at least pose some of the questions we have here, like the logic behind lower doses more frequently and it's efficacy/safety hypothesis, other PDC regimes and why, etc... They may be able to give some kind of logic and thinking. There will clearly be a lot more of the financial strategy than the drug trial strategy since that requires a whole lot more analysis, maybe some lab work, lots of industry collaboration and back and forth with the Science Advisory Comm they put in place for it.
I can't see stock moving a whole lot one way or the other until that financial roadmap is presented in more detail and they flesh out the "EBITDA positive" plan. One of the upsides would be the analysts actually like that far more than anything else it seems. If they believe the cuts and revenue growth, I'd hope they throw out the 3x Rev and 17.5x EV/EBITDA multiples for the industry to show the overreaction here. Not saying it will go roaring away unless there's some unforseen significant news they have, but would sure be nice to see a reason to get it closer to the $1.50/$2.00 valuation level based purely on the financial plan. Will be an interesting call in Feb.
Trogarzon wrote: Totally agree. But firing them can't happen before votin time in may and without big shareholders support. In the mean time, if they are scared of being fired maybe they throw us under the bus with another OO and dilute us into oblivion. Also, once they're gone what do you do, you can't replace everyone overthere, it's too late for that now. So you call another consultant to sell the company. But have you seen the biotech carnage lately, not a exactly a sellers market. So we have to endure this sh.t show until somthing occurs or that nothing occurs and we stay a 1$ company forever.